Merck Initiates P-IIb/III (MALBEC) Trial of MK-8748 for Neovascular Age-Related Macular Degeneration

Why It Matters

If MK‑8748 proves safe and effective, it could extend injection intervals and offer a novel mechanism beyond current anti‑VEGF monotherapies, reshaping the NVAMD treatment landscape.

Key Takeaways

• Merck launches MALBEC Phase IIb/III trial for MK-8748.
• Compares two MK-8748 doses against aflibercept.
• Q4W three months, then Q8W until week 48.
• Study follows patients through week 96 for safety, efficacy.
• Second NVAMD trial planned later this year.

Pulse Analysis

Neovascular age‑related macular degeneration remains a leading cause of vision loss in older adults, driving a multibillion‑dollar market for intravitreal therapies. Current standards—aflibercept, ranibizumab, and the newer faricimab—require frequent injections, imposing a substantial burden on patients and healthcare systems. Clinicians and payers are therefore eager for agents that can maintain or improve visual outcomes while reducing treatment frequency, a need that has spurred intense R&D activity across biotech and big‑pharma.

Merck’s MK‑8748 distinguishes itself by coupling a TIE2 receptor agonist with VEGF inhibition, targeting both vascular leakage and abnormal angiogenesis. The MALBEC trial’s design—two dose levels versus aflibercept, an initial quarterly regimen transitioning to eight‑weekly dosing, and a 96‑week follow‑up—aims to demonstrate not only non‑inferior efficacy but also a safety profile that could support longer dosing intervals. By incorporating individualized dosing after week 48, the study reflects a pragmatic approach to real‑world practice, where flexibility can improve adherence and outcomes.

Should the trial meet its endpoints, MK‑8748 could challenge the dominance of existing anti‑VEGF agents and provide Merck with a differentiated asset in ophthalmology. A successful outcome would also validate the bispecific strategy, potentially accelerating development of similar platforms for other retinal diseases. Investors will watch the interim data closely, as a positive readout could boost Merck’s ophthalmic pipeline valuation and influence competitive dynamics among manufacturers vying for the next generation of macular degeneration therapies.